|
End-of-day quote
Korea S.E.
2026-10-02
|
5-day change | 1st Jan Change | ||
| 1,564.00 KRW | +1.03% |
|
-4.58% | -79.91% |
Company Valuation: Aprogen Biologics Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Market Cap 1 | 524,120 | 360,706 | 200,481 | 190,684 | 130,793 | 102,540 |
| Change | - | -31.18% | -44.42% | -4.89% | -31.41% | -21.6% |
| Enterprise Value (EV) 1 | 322,016 | 238,252 | 236,145 | 361,628 | 246,492 | 279,703 |
| Change | - | -26.01% | -0.88% | 53.14% | -31.84% | 13.47% |
| P/E | 37.6x | 45.3x | 26.5x | -1.55x | -0.79x | -0.6x |
| PBR | 1.04x | 0.71x | 0.7x | 0.52x | 0.35x | 0.49x |
| PEG | - | -1.1x | -5.3x | 0x | 0x | -0.18x |
| Capitalization / Revenue | 9.83x | 6.39x | 3.08x | 2.18x | 1.94x | 1.4x |
| EV / Revenue | 6.04x | 4.22x | 3.62x | 4.14x | 3.66x | 3.82x |
| EV / EBITDA | 378x | -125x | -24x | -7.34x | -6.24x | -2.7x |
| EV / EBIT | -298x | -59.9x | -19.3x | -5.12x | -4.21x | -2.28x |
| EV / FCF | -10.8x | -2.45x | 2.37x | 25.9x | -10.3x | -3.38x |
| FCF Yield | -9.23% | -40.8% | 42.1% | 3.87% | -9.75% | -29.6% |
| Dividend per Share 2 | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - |
| EPS 2 | 5,250 | 3,000 | 2,850 | -28,122 | -12,525 | -12,932 |
| Distribution rate | - | - | - | - | - | - |
| Net sales 1 | 53,320 | 56,482 | 65,190 | 87,364 | 67,378 | 73,226 |
| EBITDA 1 | 851.3 | -1,903 | -9,837 | -49,292 | -39,486 | -103,705 |
| EBIT 1 | -1,081 | -3,975 | -12,241 | -70,690 | -58,577 | -122,889 |
| Net income 1 | 11,253 | 8,103 | 7,837 | -118,270 | -104,979 | -170,331 |
| Net Debt 1 | -202,104 | -122,454 | 35,664 | 170,944 | 115,698 | 177,163 |
| Reference price 2 | 197,250.00 | 135,750.00 | 75,450.00 | 43,500.00 | 9,930.00 | 7,785.00 |
| Nbr of stocks (in thousands) | 2,657 | 2,657 | 2,657 | 4,384 | 13,172 | 13,172 |
| Announcement Date | 3/12/21 | 3/14/22 | 3/17/23 | 3/13/24 | 3/14/25 | 3/20/26 |
1KRW in Million2KRW
Estimates
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
| - | - | - | - | 18.8M | ||
| 32.45x | 11.78x | 23.93x | 0.61% | 1,019B | ||
| 28.48x | 6.32x | 17.7x | 2.09% | 617B | ||
| 33.26x | 7.78x | 16.08x | 2.64% | 464B | ||
| 104.98x | 5.87x | 24.89x | 2.36% | 356B | ||
| 18.81x | 4.58x | 11.36x | 2.9% | 333B | ||
| 19.83x | 5.17x | 12.78x | 3.09% | 267B | ||
| 20.02x | 4.17x | 11.86x | 2.13% | 244B | ||
| 25.46x | 6.66x | 11.86x | 2.5% | 218B | ||
| -43.78x | 6.39x | 24.97x | 2.27% | 179B | ||
| Average | 26.61x | 6.52x | 17.27x | 2.29% | 369.72B | |
| Weighted average by Cap. | 31.80x | 7.61x | 18.61x | 1.96% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- A003060 Stock
- Valuation Aprogen Biologics Inc.
Select your edition
All financial news and data tailored to specific country editions
















